Aua Capital Management LLC cut its position in Celgene Corporation (NASDAQ:CELG) by 62.9% during the first quarter, Holdings Channel reports. The firm owned 1,770 shares of the biopharmaceutical company’s stock after selling 3,000 shares during the period. Aua Capital Management LLC’s holdings in Celgene Corporation were worth $220,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Motco boosted its position in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares during the period. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Celgene Corporation during the first quarter worth approximately $118,000. Carroll Financial Associates Inc. boosted its position in shares of Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 400 shares during the period. Oakworth Capital Inc. boosted its position in shares of Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 412 shares during the period. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in shares of Celgene Corporation by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 380 shares during the period. Hedge funds and other institutional investors own 78.34% of the company’s stock.

Shares of Celgene Corporation (NASDAQ:CELG) traded up 0.607% on Friday, reaching $128.355. The company had a trading volume of 1,220,455 shares. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $139.00. The firm’s 50 day moving average is $133.85 and its 200 day moving average is $124.82. The firm has a market capitalization of $100.42 billion, a PE ratio of 39.751 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company’s revenue for the quarter was up 18.7% compared to the same quarter last year. During the same period last year, the firm earned $1.44 earnings per share. On average, equities research analysts expect that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Aua Capital Management LLC Sells 3,000 Shares of Celgene Corporation (CELG)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/18/aua-capital-management-llc-sells-3000-shares-of-celgene-corporation-celg.html.

CELG has been the subject of a number of recent research reports. Credit Suisse Group set a $148.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Monday, May 22nd. Jefferies Group LLC set a $154.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Saturday, May 13th. Vetr cut Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $132.90 target price for the company. in a report on Thursday, May 11th. BTIG Research reiterated a “buy” rating and issued a $138.00 target price on shares of Celgene Corporation in a report on Monday, May 1st. Finally, Cantor Fitzgerald set a $159.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, April 27th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $147.00.

In other Celgene Corporation news, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the sale, the insider now directly owns 4,004 shares in the company, valued at $481,200.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares in the company, valued at $9,061,220.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 253,761 shares of company stock worth $33,792,445. Insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.